Table 2 |
|||
|
Clinicopathological findings in patients on sirolimus versus other immunosuppressive therapy |
|||
|
Sirolimus n = 16 |
Non-Sirolimus n = 12 |
P, value |
|
|
|
|||
|
Age, mean, years |
51.1 ± 13.25 |
54.3 ± 15.39 |
ns |
|
|
|||
|
Gender, M* |
10 (62.5) |
8 (66.7) |
ns |
|
|
|||
|
F |
6 (37.5) |
4 (33.3) |
ns |
|
|
|||
|
Time to lung biopsy, mean, months |
44.7 ± 52.04 |
128.3 ± 89.32 |
0.01 |
|
|
|||
|
Neoplasia, total, n (%) |
2 (12.5) |
7 (58.3) |
0.03 |
|
|
|||
|
Carcinoma, n (%) |
1 (6.25) |
4 (33.3) |
ns |
|
|
|||
|
Lymphoproliferative disorders, n (%) |
1 (6.25) |
3 (25.0) |
ns |
|
|
|||
|
Diffuse parenchymal lung disease, n (%) |
6 (37.5) |
3 (25.0) |
ns |
|
|
|||
|
PH, n (%) |
2 (12.5) |
1 (8.3) |
ns |
|
|
|||
|
PH and DAD, n (%) |
1 (6.25) |
0 |
- |
|
|
|||
|
PH and PAP, OP, n (%) |
1 (6.25) |
0 |
- |
|
|
|||
|
OP, n (%) |
2 (12.5) |
1 (8.3) |
ns |
|
|
|||
|
PAP, n (%) |
0 |
1 (8.3) |
- |
|
|
|||
|
Necrosis/infectious granulomas, n (%) |
4 (25.0) |
1 (8.3) |
ns |
|
|
|||
|
Minimal histological findings, n (%) |
4 (25.0) |
1 (8.3) |
ns |
|
|
|||
|
(*) -M male; F female; PH pulmonary hemorrhage; DAD diffuse alveolar damage; PAP pulmonary alveolar proteinosis; OP organizing pneumonia; ns, not statistically significant |
|||
|
Kirby et al. Diagnostic Pathology 2012 7:25 doi:10.1186/1746-1596-7-25 |
|||
